Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: clinical setbacks in melanoma and prostate cancer; Chinese pharma firms face US listing pressures; Eisai hands Aduhelm to Biogen; and Scrip Asks what 2022 holds for digital and telehealth.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 18 March 2022, including: clinical setbacks in melanoma and prostate cancer; Chinese pharma firms face US listing pressures; Eisai Co., Ltd. hands Aduhelm to Biogen, Inc.; and Scrip Asks what 2022 holds for digital and telehealth.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Nektar/BMS’s IL-2 Inhibitor Melanoma Failure Leaves Room For Other Contenders" - Scrip, 14 Mar, 2022.)
(Also see "Rare Setback For Merck & Co And AstraZeneca’s Keytruda-Lynparza Combo In Prostate Cancer" - Scrip, 16 Mar, 2022.)
(Also see "Financial Decoupling: China Biotechs Brace For Potential US Delistings, Softening Economy" - Scrip, 16 Mar, 2022.)
(Also see "Eisai Gives Full Aduhelm Responsibility To Biogen Under Amended Agreement" - Scrip, 14 Mar, 2022.)
(Also see "Scrip Asks…What Does 2022 Hold For Biopharma? Part 6: Digital And Telehealth" - Scrip, 16 Mar, 2022.)